South Korean approval and production deal for Moderna's COVID-19 vaccine

24 May 2021

Last Saturday, US biotech Moderna (Nasdaq: MRNA) announced that the Ministry of Food and Drug Safety of South Korea (MFDS) has approved the company’s application for conditional marketing authorization for its mRNA vaccine against COVID-19.

GC Pharma in South Korea is the company’s marketing authorization holder and distributor of Moderna’s COVID-19 vaccine for the South Korea.

The approval is based on the totality of scientific evidence shared by the company, including a data analysis from the pivotal Phase III clinical study announced on November 30, 2020. South Korea has secured access to 40 million doses of COVID-19 Vaccine Moderna.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK